Dornase Alfa Pulmozyme Inhalation Solution
date: label: date made
content: ca 2013
label: product expiration date
content: 2014-08
name: label: maker
content: Genentech, Inc.
notes: label: Description (Brief)
content: (From insert) Daily administration of Pulmozyme Inhalation Solution in conjunction with standard therapies is indicated in the management of cystic fibrosis patients to improve pulmonary function. In patients with an FVC of greater than or equal to 40% of predicited, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requireing parenteral antibiotics. Safety and efficacy of daily administration have not been demonstrated in patients for longer than twelve months.
label: Location
content: Currently not on view
place: label: place made
content: United States: California, South San Francisco
setName: label: See more items in
content: Medicine and Science: Medicine
label: See more items in
content: Health & Medicine
label: See more items in
content: The Antibody Initiative
creditLine: label: Credit Line
content: Gift of Genentech, Inc.
dataSource: label: Data Source
content: National Museum of American History
identifier: label: ID Number
content: 2013.0069.03
label: catalog number
content: 2013.0069.03
label: accession number
content: 2013.0069
objectType: label: Object Name
content: pharmaceutical
label: Object Name
content: biological
physicalDescription: label: Physical Description
content: plastic (overall material)
label: Physical Description
content: cardboard (overall material)
label: Physical Description
content: dornase alfa, 2.5 mg per ampule (overall ingredient)
label: Measurements
content: overall: 4 1/2 in x 4 3/4 in x 2 1/2 in; 11.43 cm x 12.065 cm x 6.35 cm
label: Measurements
content: foil packet: 1/2 in x 4 1/4 in; 1.27 cm x 10.795 cm
label: Measurements
content: overall: 4 1/2 in x 4 3/4 in x 2 5/8 in; 11.43 cm x 12.065 cm x 6.6675 cm